Healthcare Professional’s Experiences & Perceptions of Switching Brands of oral SACT – Survey

Dear BOPA members

In cancer care, little is known about the impact of specific brands of oral SACT medication or how healthcare professionals respond and process brand switches of oral SACT. To understand this, we would like to gather the views of healthcare professionals involved in cancer care, on their perspectives and experiences on brand switching of oral SACT. Insights will be combined with data from the NIHR-funded SWITCH project, to improve cancer treatment delivery.

We would be very grateful if you would complete this online survey, which will take 10-15 minutes, by scanning the QR code or through this link: https://qualtrics.ucl.ac.uk/jfe/form/SV_dj0l16wIjCFIbWe

If you have any problems please email Pinkie Chambers : [email protected]

We would like responses by November 28th

Many thanks
Jessica Lim

4th Year MPharm Student, UCL School of Pharmacy

Supervisors: Dr Pinkie Chambers, Dr Zoe Moon, Rebecca Todd

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article